Skip to main content
OpenTrials
Completed

NCT Number: NCT02430233

Vaginal Progesterone for the Prolongation of Pregnancy After Arrested Pre-term Labor

Patients diagnosed with arrested pre-term labor following tocolytics at 24-34 gestational weeks will be randomly allocated to receive either vaginal micronized progesterone 400 mg/day or no treatment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Poriya Medical Center, Tiberias, North, Israel

Loading trial locations.

About this study

Since progesterone derivatives are useful in preventing preterm labor in cases of risk factors or previous preterm labor, we hypothesize that they will also show efficacy in pregnancy prolongation in women whose preterm labor was arrested following tocolytic treatment.

Patients diagnosed with arrested pre-term labor following tocolytics at 24-34 gestational weeks will be randomly allocated to receive either vaginal micronized progesterone 400 mg/day or no treatment.

This study has the potential to find a treatment to prevent preterm labor and thus to reduce neonatal morbidity and mortality.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age
  • Tocolytic treatment between 24+0 and 34+0 weeks
  • Patient's consent to participate in this study
  • 24 hours after tocolytic initiation and up to 3 days after finishing the tocolytic treatment
  • Arrest of preterm labor

Exclusion criteria

  • Contraindication to ongoing pregnancy including:
  • Suspected amnionitis during testing for eligibility- evidence of active infection including temperature ≥ 38.0°C and uterine tenderness, foul-smelling vaginal discharge, maternal tachycardia of 120 beats per minute or greater, or sustained fetal tachycardia of 160 beats per minute or greater
  • Evidence of significant placental abruption (contractions and significant bleeding from placental origin)
  • Intrauterine fetal death diagnosed at the time of admission
  • Major fetal malformation
  • Known maternal allergy to progesterone
  • Current use of progesterone at the time of admission
  • Epilepsy
  • Breast cancer
  • PPROM (preterm premature rupture of membranes) during testing for eligibility
  • Age below 18 years
  • Known active liver disease (elevated liver enzymes at twice the upper normal limit according to medical history or blood test that were taking doring standard medical care)
  • History of deep vein thrombosis
  • Major active psychiatric disorders (major affective disorders and psychotic disorders)
  • Uncontrolled chronic hypertension
  • Heart failure
  • Chronic renal failure
  • Pre-gestational diabetes with known target organ damage
  • History of spontaneous preterm delivery
  • Previous tocolytic treatment during the current pregnancy

Treatment and study plan

micronized progesterone 400 mg (Utrogestan)

Drug

participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)

Other names: Utrogestan- 200mg×2 PV(per vagina) per day

Primary outcomes

  1. The mean number of days from enrollment to delivery

    Time frame: Up to 18 weeks

  2. The rate of preterm spontaneous delivery

    Time frame: Up to 13 weeks

    defined as spontaneous labor or preterm delivery following induction/cesarean section due to preterm premature rupture of membranes prior to 37 weeks of gestation

Secondary outcomes

  1. Number of days from recruitment to repeated preterm labor episode or preterm premature rupture of membranes, up to 37 weeks of gestation

    Time frame: Up to 13 weeks

  2. Pregnancy prolongation beyond one week

    Time frame: Up to 18 weeks

  3. Need for repeated acute tocolysis

    Time frame: Up to 13 weeks

  4. Number of hospitalizations and length of stay until 36.6 gestational weeks

    Time frame: Up to 13 weeks

  5. The rate of preterm spontaneous labor (defined as spontaneous labor or preterm premature rupture of membranes prior to 37 weeks of gestation)

    Time frame: Up to 13 weeks

  6. Admission to the NICU (neonatal intensive care unit)

    Time frame: From delivery and up to 28 days

  7. Length of NICU stay

    Time frame: From delivery and up to 3 months

  8. Length of neonate hospital stay

    Time frame: From delivery and up to 3 months

  9. Fetal/neonatal death

    Time frame: Around delivery

  10. Birth weight and the rate of small for gestational age neonates

    Time frame: Around delivery

  11. The rate of neonatal complications

    Time frame: From delivery and up to 3 months

    including transient tachypnea, RDS (respiratory distress syndrome), bronchopulmonary dysplasia, ventilatory support, supplemental oxygen, IVH (intraventricular hemorrhage), NEC (necrotizing enterocolitis), PDA (patent ductus arteriosus), retinopathy, neonatal sepsis, and congenital abnormalities not previously identified (specifically genital abnormalities).

  12. The rate of chorioamnionitis and endometritis

    Time frame: around delivery and up to 1 week post-partum

  13. Adverse medication reactions

    Time frame: Up to 13 weeks

  14. Postpartum hemorrhage

    Time frame: From delivery and up to 1 week post-partum

  15. Revision of uterine and cervix and reasons for the procedure

    Time frame: During the 48 hours from delivery

  16. Urinary tract or vulvovaginal infection until 36.6 weeks

    Time frame: Up to 13 weeks

Sponsors and collaborators

Lead sponsor

HaEmek Medical Center, Israel

Other

Registry information

Official study title

Vaginal Progesterone for the Prolongation of Pregnancy After Arrested Pre-term Labor - Randomized Double Blind Placebo Controlled Trial

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Apr 30, 2015
Registry last updated
Feb 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.